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ing rates of NI per 1000 cases ranged from 11 to 175 per year for
ofﬁce-based encounters and 0 to 311 for hospital-based encoun-
ters. Adamantane prescribing rates ranged from 23 to 194 for
ofﬁce-based encounters and 5 to 172 for hospital-based en-
counters. Odds ratios of adamantanes rather than NIs were 26.6
(P < 0.0001) for 1999, 0.034 for 2000, 0.011 for 2001, 0.058 for
2002, 0.002 for 2003, 0.178 for 2004 (p < 0.001). Whites (OR:
9.4, p < 0.001), females (OR: 1.8. p < 0.001), patients under 55
(OR: 0.4–0.53, p < 0.001), and patients from the West (OR:
2.7–33.9, p < 0.001) were most likely to get adamantanes. CON-
CLUSION: NI usage slowly increased from 1999–2005. Ofﬁce-
based encounters had a greater rate of prescriptions for
adamantanes than hospital-based encounters. In months other
than ﬂu season patients were less likely (OR: 0.06, p < 0.001) to
get adamantanes. General practitioners were less likely (OR: 0.5,
p < 0.001) to prescribe adamantanes than other specialties.
Patient age, race, sex, physician specialty, and geographic region
were signiﬁcantly related to prescribing patterns. In 2005,
patients were more likely to get adamantanes in spite of high
incidence of adamantane resistant viruses.
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OBJECTIVE: To estimate the number of patients with potential
major, moderate or major/moderate drug-drug interactions
(DDI) between oral antipsychotics and coprescribed drugs
within a managed care population (MCP). METHODS: Litera-
ture and drug information resources were used to identify and
classify clinical severity of potential antipsychotic DDIs based
on cytochrome P450 metabolism of antipsychotics and copre-
scribed drugs. PHARMetrics pharmacy claims for one year
(June 2004 zC July 2005) from individuals with antipsychotic
claims (including oral risperidone, olanzapine, quetiapine,
ziprasidone, aripiprazole, clozapine, oral haloperidol and per-
phenazine) were evaluated. Patients with 10 days of overlap
with a potentially interacting drug of severity grade 1 (major),
2 (moderate) or 4 (major/moderate) were identiﬁed. Drug Facts
& Comparisons severity grading scale was used to determine
drugs that met these criteria. Results were extrapolated to
provide a population-based prediction of the risk for potential
DDIs. Recent national market-share (MS) data (IMS prescrip-
tion audit 4Q06) for each antipsychotic were multiplied by the
percentage of potential projected interactions to determine the
number of patients at risk for DDIs in a cohort of 10,000
patients prescribed antipsychotics. RESULTS: Of the 73,562
patients who met study inclusion criteria, 8551 (11.6%)
patients had at least one potential DDI of severity grade 1, 2 or
4. Depending on the antipsychotic dispensed, percentage of
potential DDIs ranged from 0% to 26.8%. Applied to a cohort
of 10,000 patients, over 1162 (11.6%) patients could poten-
tially experience a grade 1, 2 or 4 DDI. Oral risperidone
(26.8% MS) had the highest potential for DDIs (n = 676) and
quetiapine (30.4% MS) had the second highest potential for
DDIs (n = 137). Ziprasidone (5.7% MS) had no potential P450
DDI interactions of severity grade 1, 2 or 4. CONCLUSION:
Prevalence of potentially serious DDIs due to interactions with
cytochrome P450 metabolic activity is high in patients being
treated with antipsychotics.
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OBJECTIVE: The objectives of this analysis were to: Identify a
population of schizophrenia patients treated within a commer-
cial managed care environment. Describe and compare the
prevalence of conditions associated with metabolic syndrome in
patients treated with antipsychotics agents. METHODS: Using
integrated medical and pharmacy claims data (obtained from
the IMS/Pharmetrics Patient-centric Database), patients were
included in this analysis based on the presence of a diagnosis of
schizophrenia (ICD-9 code 295.*) in 2005. Clinical and eco-
nomic information related to the treatment of schizophrenia
were captured using Episode Treatment Group™ (ETG™)
episode-building software. RESULTS: In 2005, 8594 schizo-
phrenia patients were identiﬁed; within this population, the
average age was 45.7 years and 46% was male. Co-morbid
conditions included bipolar disorders (in 23.7% of patients),
anxiety disorder (12.7%), substance dependence (11.7%), and
depression (7.9%). Overall (among the entire identiﬁed patient
population), 75.6% of patients used antipsychotics; 57.4% used
only atypical agents, 9.1% used only conventional agents and
9.1% used both. Overall, 48.6% of patients had at least one of
the following conditions, considered markers for metabolic
syndrome: diabetes, hyperlipidemia, hypertension, or obesity.
Among patients treated with antipsychotics, prevalence of these
conditions was lowest in those treated only with atypical agents
(46.5% with at least one condition), higher in patients treated
only with conventional agents (55.5% with at least one
condition), and highest in patients with use of both classes of
antipsychotic agents. CONCLUSION: The schizophrenia popu-
lation observed in this analysis reﬂected a lower prevalence
of presumed metabolic syndrome in groups treated with
atypical antipsychotic agents. This observation contradicts other
research. This disparity may be attributable to differences in
patient demographics or other confounding factors, but none-
theless warrants further study.
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OBJECTIVE: To examine a sample of patients admitted to hos-
pitals with drug abuse for some inpatient treatment in order to
look for trends that may lead to a better understanding of the
data and of which groups seem to be most at risk for this
ailment. METHODS: Data were taken from a ten percent
sample of the National Inpatient Sample from 2004. A data
sample of 7903 inpatients from 2004 was organized, plotted,
graphed, and put into tables in order to best understand the
patterns and variances. Logistic regression models were created
to compare variables and help to predict age and mortality of
the inpatients. The data were preprocessed to include only the
most frequently occurring diagnosis and procedure codes.
RESULTS: Frequency of cases of drug abuse showed spikes
near the ages of 40 and 80, with the African Americans and
males dominant at the 40 spike and the Caucasians and males
at the 80 spike. Code variables for rehabilitation, blood trans-
fusion, respiratory intubation, hypertension, heart disease,
congestive heart failure, urinary tract infection, cardiac dys-
rhythmias, pulmonary disease, ﬂuid disorder, CT head
scan, gastrointestinal endoscopy, psychiatric therapy, physical
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